Previous Close | 2.3700 |
Open | 2.3700 |
Bid | 0.0000 x 3000 |
Ask | 0.0000 x 800 |
Day's Range | 2.3501 - 2.4700 |
52 Week Range | 2.3500 - 6.7200 |
Volume | |
Avg. Volume | 205,527 |
Market Cap | 61.472M |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4880 |
Earnings Date | Nov 14, 2022 - Nov 21, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ETON
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -300% and 5.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on rare disease strategyU.S. Food and Drug Administration (FDA) Approval of Zonisade™ (zonisamide oral suspension) DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.